logo-loader

Zynerba Pharmaceuticals announces results from phase 2 Zygel trial

Published: 11:13 08 Dec 2022 EST

Zynerba Pharmaceuticals CEO Armando Anido joins Natalie Stoberman from the Proactive studios to share results of its phase 2 trial of Zygel.

Anido says data from the Phase 2 INSPIRE trial with Zygel in children and adolescents with with 22q11.2 deletion syndrome has continued to show improvement in anxiety-related and behavioural symptoms.

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

22 minutes ago